DiscoveryProbe™ FDA-approved Drug Library: A High-Throughput Resource for Drug Repositioning and Pharmacological Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds approved by the FDA, EMA, HMA, CFDA, and PMDA, or listed in major pharmacopeias (APExBIO). Each compound is provided as a 10 mM DMSO solution and is stable for 12 months at -20°C and up to 24 months at -80°C. The library supports high-throughput (HTS) and high-content screening (HCS) workflows, facilitating drug repositioning and pharmacological target identification (Rashid et al., 2021). Representative drugs include doxorubicin, metformin, and atorvastatin, spanning diverse mechanisms of action. The collection is validated for use in oncology, neurodegenerative disease, and signal pathway research, and is distributed by APExBIO (product page).

Biological Rationale

The systematic screening of known, approved drugs accelerates the discovery of novel therapeutic indications, a process known as drug repositioning. FDA-approved compounds have established safety, pharmacokinetic, and pharmacodynamic profiles, reducing the risk and cost associated with early-phase drug development (Rashid et al., 2021). Recent advances in high-throughput screening enable rapid evaluation of thousands of compounds across diverse biological models, such as triple-negative breast cancer (TNBC) and neurodegenerative disease cell lines. By leveraging libraries like DiscoveryProbe™, researchers can systematically interrogate pharmacological space for new signal pathway regulators, enzyme inhibitors, and receptor modulators.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library is composed of compounds with well-characterized mechanisms, including:

• Receptor agonists and antagonists: Compounds modulating G-protein coupled receptors, nuclear receptors, and tyrosine kinase receptors.
• Enzyme inhibitors: Targeting kinases, proteases, phosphatases, and metabolic enzymes.
• Ion channel modulators: Affecting voltage-gated and ligand-gated channels.
• Signal pathway regulators: Interfering with PI3K/mTOR, MAPK, Wnt, and Notch signaling.

Each compound is provided in a standardized 10 mM DMSO solution, facilitating direct dosing and ensuring reproducibility in HTS and HCS applications. The diversity of mechanisms supports the identification of synergistic drug combinations and the elucidation of complex biological pathways (see DiscoveryProbe™ overview; this article details updates in screening for pharmacological target identification).

Evidence & Benchmarks

• High-throughput screening (HTS) of 1,363 clinically used drugs identified synergistic drug combinations effective against triple-negative breast cancer (TNBC) cell lines (Rashid et al., 2021).
• The combination of KPT-330 (an XPO1 inhibitor) and GSK2126458 (a PI3K/mTOR inhibitor) reduced tumor burden in vivo in basal-like TNBC patient-derived xenografts by >40% compared to monotherapy controls (Rashid et al., 2021).
• The DiscoveryProbe™ FDA-approved Drug Library supports stable compound storage for 12 months at -20°C and up to 24 months at -80°C in 10 mM DMSO solution (APExBIO).
• Researchers using this library have identified novel pharmacological modulators in neurodegenerative disease models, facilitating rapid pathway elucidation (internal review; this article provides updated evidence on HTS in disease models).
• HTS enables identification of cytotoxic compounds and synergistic drug pairs, accelerating the translation of preclinical findings to clinical research (Rashid et al., 2021).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• Drug repositioning screening: Rapidly evaluates approved drugs for new indications in oncology, neurology, and immunology.
• Pharmacological target identification: Systematic testing across disease models to reveal new therapeutic targets (internal article; this article clarifies compound diversity and data structure for machine-readability).
• Cancer research drug screening: Enables identification of cytotoxic and synergistic anti-cancer compounds, particularly in chemoresistant cancers such as TNBC (Rashid et al., 2021).
• Neurodegenerative disease drug discovery: Facilitates mechanistic studies in Alzheimer’s and Parkinson’s disease models (internal article).
• Signal pathway regulation and enzyme inhibitor screening: Supports pathway deconvolution and validation of pharmacological hypotheses.

Common Pitfalls or Misconceptions

• The library does not include investigational or preclinical compounds; only drugs with recognized regulatory approval or pharmacopeia listing are present.
• Compounds are provided in DMSO and may be incompatible with DMSO-sensitive assays or organisms.
• HTS identifies candidates but does not guarantee clinical efficacy; functional validation and in vivo studies are required.
• Not all mechanisms or pathways may be represented; gaps may exist for rare targets or orphan diseases.
• Drug concentrations must be optimized for each assay; the standard 10 mM solution may require dilution to prevent cytotoxicity or off-target effects.

Workflow Integration & Parameters

Each compound in the DiscoveryProbe™ FDA-approved Drug Library is provided as a 10 mM DMSO solution, delivered in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes. Storage at -20°C ensures stability for 12 months; -80°C extends shelf-life up to 24 months. Shipping is performed on blue ice for evaluation samples and at room temperature or on blue ice for larger shipments upon request (APExBIO).

For integration into automated HTS or HCS platforms:

• Directly compatible with robotic liquid handling systems.
• Supports single-point, dose-response, and combinatorial screening formats.
• Barcode tracking ensures traceability and minimizes sample mix-up.
• Data output is amenable to statistical modeling, machine learning, and cheminformatics analysis.

For a more detailed comparison of workflow integration and data structuring in automated screening, see this article; the present piece extends the discussion to regulatory compliance and compound provenance.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) by APExBIO provides a validated, regulatory-vetted platform for high-throughput and high-content screening. Its breadth and stability support reproducible pharmacological research, enabling drug repositioning, mechanistic studies, and identification of new therapeutic targets across oncology, neurology, and beyond. By standardizing compound preparation and metadata, DiscoveryProbe™ facilitates machine-readable research pipelines and accelerates the translation of preclinical findings. Ongoing HTS studies continue to expand the utility of such libraries in addressing chemoresistance and uncovering novel drug synergies (Rashid et al., 2021).

For comprehensive details, visit the DiscoveryProbe™ FDA-approved Drug Library product page.